SBLi Program

ANT3310 is a novel, potent and specific bacterial serine ß-lactamase (SBL) inhibitor that displays excellent inhibitory activity that includes both KPC- and OXA -type carbapenemases. It will be administered intravenously in conjunction with meropenem for treating hospital-acquired infections (HAIs) caused by Gram-negative pathogens, including carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB), which are WHO Priority Pathogens. CRAB is spreading worldwide, accounting for more than 70% of A. baumannii in many countries and is one of the most common causes of HAIs. ANT3310 has received QIDP status from the FDA for complicated urinary tract infection (cUTI), complicated intra-abdominal infection (cIAI) and nosocomial pneumonia (NP). Preclinical development has been completed. Preparation for Phase 1 clinical studies is in progress.